Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

Mayo Clinic

Status

Completed

Conditions

Thyroid Gland Follicular Carcinoma

Treatments

Procedure: Single Photon Emission Computed Tomography

Radiation: Iodine I-123

Procedure: Planar Imaging

Procedure: Computed Tomography

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT05591092

20-010663 (Other Identifier)

NCI-2022-03573 (Registry Identifier)

Details and patient eligibility

About

This study evaluates radioiodine planar and SPECT/CT imaging with iodine-123 in patients with follicular thyroid nodules prior to surgery. Because biopsy alone is not sufficient to distinguish between malignant follicular thyroid nodules and benign follicular thyroid nodules, patients with follicular thyroid lesions are referred for surgery for further evaluation. A non-invasive imaging method that can accurately determine malignancy in follicular thyroid nodules would be valuable in patient management and could potentially spare patients unnecessary surgery. Planar imagine uses a gamma camera to obtain 2D images and SPECT/CT imaging is a special type of CT scan in which a small amount of a radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the tumor cells. Radioiodine planar and SPECT/CT imaging may be more accurate in distinguishing between benign follicular thyroid nodules and malignant follicular thyroid nodules to help reduce the need for surgery.

Full description

PRIMARY OBJECTIVES:

I. Determine the proportion of benign nodules appearing as hot/warm on radioiodine scans (nodule uptake >= uptake in normal thyroid tissues).

II. To identify a possible relationship between iodine-123 (I-123) uptake on planar and single-photon emission computerized tomography (SPECT)/computerized tomography (CT) images and malignancy on surgical pathology in thyroid nodules that were previously identified by fine-needle aspiration (FNA) as indeterminate follicular neoplasm.

III. Examine correlations between intensity of uptake in follicular nodules before surgery (standard uptake values [SUV] on the quantitative reconstructions from our Veriton SPECT/CT scanner and nodule-to-normal thyroid background ratios on planar and SPECT images) and pathology findings and determine a SUV threshold that best distinguishes between benign and malignant nodules.

IV. Compare the usefulness of conventional planar imaging versus SPECT/CT imaging for thyroid nodules, in order to inform our optimal clinical protocol.

V. Establish an imaging protocol best suited for measuring uptake in small thyroid nodules.

OUTLINE:

Patients receive iodine-123 orally (PO) and then undergo planar imaging and a SPECT/CT scan on study.

Enrollment

2 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age > 18 years
Any gender
Patients will have had no therapy for their thyroid nodule prior to enrollment
Negative urine pregnancy test within 48 hours before the administration of radiopharmaceutical in women of childbearing potential
Follicular neoplasm or suspicious of follicular neoplasm, cytopathology on biopsy of thyroid nodule
Any outside fine needle aspiration (FNA) reports are to be reviewed by a Mayo pathologist
Nodules 1-4 cm with solid appearance on ultrasound
Ultrasound images and report documented in medical record, including the size of the nodule and location (upper, mid or lower portion of the thyroid lobe)
At least 2/3 of either thyroid lobe without nodules should be present to allow for the measurement of uptake in unaffected thyroid tissue
Thyroid stimulating hormone (TSH) 0.3-3.0 mIU/L
Patient is scheduled or being considered for surgical resection of the nodule
I-123 planar and Single Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) can be scheduled at least 2 days after biopsy and before surgery

Exclusion criteria

Recent iodinated contrast, including intravenous (IV) and oral CT contrast or interventional vascular or cardiac study (within 6 weeks)
Hurthle cell adenoma
Current thyroid hormone supplementation
Current use of anti-thyroid medications (methimazole or propylthiouracyl)
Less than 2 days after thyroid nodule FNA/biopsy
Presence of another nodule of similar size in the same area of thyroid lobe, which could impair localization of the nodule on SPECT/CT images
Less than 2/3 of normal thyroid tissue present in either thyroid lobe without nodules
Positive pregnancy test
All women who are breastfeeding